- Home
- FMC vs BPMC Comparison
FMC vs BPMC Comparison
Compare FMC & BPMC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FMC
- BPMC
- Stock Information
- Founded
- FMC 1910
- BPMC 2008
- Country
- FMC United States
- BPMC United States
- Employees
- FMC N/A
- BPMC N/A
- Industry
- FMC Major Chemicals
- BPMC Biotechnology: Pharmaceutical Preparations
- Sector
- FMC Industrials
- BPMC Health Care
- Exchange
- FMC Nasdaq
- BPMC Nasdaq
- Market Cap
- FMC 4.5B
- BPMC 5.8B
- IPO Year
- FMC N/A
- BPMC 2015
- Fundamental
- Price
- FMC $40.38
- BPMC $89.84
- Analyst Decision
- FMC Hold
- BPMC Buy
- Analyst Count
- FMC 14
- BPMC 20
- Target Price
- FMC $52.57
- BPMC $125.00
- AVG Volume (30 Days)
- FMC 2.9M
- BPMC 999.2K
- Earning Date
- FMC 05-05-2025
- BPMC 05-01-2025
- Dividend Yield
- FMC 5.75%
- BPMC N/A
- EPS Growth
- FMC N/A
- BPMC N/A
- EPS
- FMC 2.71
- BPMC N/A
- Revenue
- FMC $4,246,100,000.00
- BPMC $508,824,000.00
- Revenue This Year
- FMC N/A
- BPMC $45.43
- Revenue Next Year
- FMC $6.70
- BPMC $32.80
- P/E Ratio
- FMC $14.89
- BPMC N/A
- Revenue Growth
- FMC N/A
- BPMC 104.04
- 52 Week Low
- FMC $33.80
- BPMC $80.68
- 52 Week High
- FMC $68.72
- BPMC $121.90
- Technical
- Relative Strength Index (RSI)
- FMC 47.60
- BPMC 41.73
- Support Level
- FMC $39.55
- BPMC $84.59
- Resistance Level
- FMC $42.36
- BPMC $90.00
- Average True Range (ATR)
- FMC 1.35
- BPMC 3.50
- MACD
- FMC 0.87
- BPMC 0.10
- Stochastic Oscillator
- FMC 71.83
- BPMC 43.28
About FMC FMC Corporation
FMC is a pure-play global crop protection company with a fairly balanced product portfolio across geographies and crop exposure. Through acquisitions, FMC is now one of the five largest patented crop protection companies and focuses on the development of new products, including biologicals, through its research and development pipeline.
About BPMC Blueprint Medicines Corporation
Blueprint Medicines Corp is a biopharmaceutical company. It is focused on improving the lives of patients with diseases driven by abnormal kinase activation. The company has developed a small molecule drug pipeline in cancer and a rare genetic disease. Its drug candidates includes AYVAKIT for the treatment of systemic mastocytosis, BLU-808 a potential treatment for mast cell disorders, including chronic urticaria, sleep disruption and other related diseases. It also has other drugs in its pipeline such as BLU-956, BLU-222 for treatment of breast cancer.